Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741790 | 1.00 | CCR2 (0.38) | CCR2SMYD3CCR5SLC6A12SLC6A11 | |
| SCHEMBL19715160 | 0.89 | CCR2 (0.36) | CCR2SMYD3SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL5031941 | 0.83 | BTK (0.48) | CCR2 | |
| SCHEMBL5767379 | 0.82 | SMYD3 (0.40) | CCR2SMYD3CCR5 | |
| SCHEMBL3736911 | 0.82 | SMYD3 (0.40) | CCR2SMYD3CCR5 | |
| SCHEMBL3736908 | 0.82 | SMYD3 (0.40) | CCR2SMYD3CCR5 | |
| SCHEMBL3736900 | 0.79 | SLC6A12 (0.35) | CCR2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3736905 | 0.79 | SLC6A12 (0.35) | CCR2SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3739084 | 0.78 | CCR2 (0.31) | CCR2SMYD3SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL3739078 | 0.78 | CCR2 (0.31) | CCR2SMYD3SLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1656345-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CCR2 5/4885SMYD3 3149/4885CCR5 8/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | CCR2 5/4885SMYD3 3149/4885CCR5 8/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CCR2 5/4885SMYD3 3149/4885CCR5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.